IRIS
RASI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.639
EU - Europa 2.430
AS - Asia 1.265
Continente sconosciuto - Info sul continente non disponibili 10
SA - Sud America 8
AF - Africa 4
OC - Oceania 4
Totale 31.360
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.608
SG - Singapore 547
CN - Cina 518
UA - Ucraina 442
DE - Germania 356
IT - Italia 355
IE - Irlanda 295
PL - Polonia 283
FR - Francia 238
SE - Svezia 135
GB - Regno Unito 119
KR - Corea 118
FI - Finlandia 90
RU - Federazione Russa 76
CA - Canada 30
JP - Giappone 24
IN - India 15
BE - Belgio 9
HK - Hong Kong 9
UZ - Uzbekistan 9
EU - Europa 8
CZ - Repubblica Ceca 7
IL - Israele 7
AT - Austria 5
NL - Olanda 5
AU - Australia 4
BR - Brasile 4
ES - Italia 4
VN - Vietnam 4
CL - Cile 3
IR - Iran 3
RO - Romania 3
TR - Turchia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CH - Svizzera 2
GR - Grecia 2
NG - Nigeria 2
SA - Arabia Saudita 2
DM - Dominica 1
EC - Ecuador 1
EG - Egitto 1
GH - Ghana 1
HU - Ungheria 1
ID - Indonesia 1
LK - Sri Lanka 1
LV - Lettonia 1
MY - Malesia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 31.360
Salva come PNG Salva come JPEG
Città #
Woodbridge 8.350
Wilmington 7.775
Houston 6.551
Ann Arbor 807
Fairfield 695
Singapore 477
Jacksonville 414
Chandler 381
Ashburn 343
Dublin 293
Kraków 283
Seattle 265
Cambridge 248
Medford 242
Beijing 216
Dearborn 163
Santa Clara 114
Lawrence 106
Rome 100
Zhengzhou 87
Hangzhou 77
Mülheim 70
New York 52
San Diego 48
Milan 35
Moscow 31
Menlo Park 29
Boardman 26
Falls Church 26
Toronto 24
Shanghai 22
Hefei 19
University Park 19
Nanjing 18
San Mateo 18
London 16
Norwalk 16
Verona 16
Redwood City 13
Yongsan-gu 13
Mountain View 11
Bologna 10
Kunming 10
Fukuoka 9
Saint Petersburg 9
Brussels 8
Brno 7
Chengdu 7
Nürnberg 7
Palo Alto 7
Detroit 6
Jinan 6
Nuremberg 6
Seoul 6
Auburn Hills 5
Florence 5
Guangzhou 5
Helsinki 5
Marano Di Napoli 5
Munich 5
Nanchang 5
Redmond 5
Ridgeland 5
Vienna 5
Chongqing 4
Hanoi 4
Indiana 4
Kilburn 4
Leawood 4
Naples 4
Shenyang 4
Washington 4
Ahmedabad 3
Alghero 3
Baotou 3
Changsha 3
Chiswick 3
Council Bluffs 3
Forlì 3
Hyderabad 3
Los Angeles 3
San Francisco 3
São Paulo 3
Tai Po Kau 3
Yangcheon-gu 3
Ypsilanti 3
Abuja 2
Acton 2
Aliminusa 2
Amsterdam 2
Augusta 2
Berlin 2
Camerino 2
Clearwater 2
Halifax 2
Incheon 2
Lappeenranta 2
Lastra a Signa 2
Madrid 2
Mapo-gu 2
Totale 28.759
Salva come PNG Salva come JPEG
Nome #
Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance 499
Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats 487
Thymosin alpha 1: From bench to bedside 482
Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1. 460
ANTITUMOR EFFECT OF COMBINED TREATMENT WITH THYMOSIN ALPHA-1 AND INTERLEUKIN-2 AFTER 5-FLUOROURACIL IN LIVER METASTASES FROM COLORECTAL-CANCER IN RATS 442
Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/β-catenin signaling 440
Combination low-dose lymphoblastoid interferon and thymosin alpha(1) therapy in the treatment of chronic hepatitis B 436
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 436
Thymosin alpha 1: from bench to bedside 429
Feasibilty of in utero DNA vaccination following naked gene transfer into pig fetal muscle: transgene expression, immunity and safety 427
Combined treatment with thymosin-alpha 1 and low dose interferon-alpha after dacarbazine in advanced melanoma 424
Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer 424
Access to patient-level trial data--a boon to drug developers 422
TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. 420
Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union 418
Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis 414
Combination therapy with BRMs in cancer and infectious diseases 413
Treatment of aspergillus infection with thymosin alpha 1 412
Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application 406
The risks of risk aversion in drug regulation 404
Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma 403
Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1 402
Drug policy for an aging population--the European Medicines Agency's geriatric medicines strategy 402
Differential expression of a new tumor-associated antigen, TLP, during human colorectal cancer tumorigenesis 401
Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer 394
Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats 392
Combination low-dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B 387
Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies 386
null 385
Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling 384
Anti-tumour immunogens and vaccines 384
Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a 381
null 380
The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation 375
Combination therapy with BRMs in cancer and infectious diseases 375
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 372
comparative cellular signal patway analysis of metastatic colorectal cancer in human and preclinical animal model 372
High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma 371
An audience with Guido Rasi. Interview by Asher Mullard 370
Thymosin alpha 1 in combination with cytokines and chemotherapy for the treatment of cancer 367
Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee 366
Evaluation of antigen specific recognition and cell mediated cytotoxicity by a modified lysispot assay in a rat colon carcinoma model 365
Combination thymosin alpha(1) and lymphoblastoid interferon treatment in chronic hepatitis C 363
Straight talk with...Guido Rasi. Interview by Roxanne Khamsi 358
Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional healthcare providers 357
ACTIVATION OF HUMAN ENDOGENOUS RETROVIRUS-K AND PRODUCTION OF INFECTIOUS VIRUS-LIKE PARTICLES IN HUMAN MELANOMA CELLS ABS -0153 357
Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice 354
nerve growth factor (ngf) and cirrhosis: a possible new marker of progression to hepatocellular carcinoma (hcc) 353
Microfabricated biocapsules provide short-term immunoisolation of insulinoma xenografts 350
differentiation therapy: in vitro evidence making cyanidin-3-o--glucopiranoside useful for prevention and treatment of melanoma 350
Fifty years after thalidomide; what role for drug regulators? 349
Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma 348
up-regulation of melanocytic differentiation antigens induced by cyanidin-3-o--glucopyranoside in human melanoma cells. 347
Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response 346
COMPARATIVE CELLULAR SIGNAL PATWAY ANALYSIS OF METASTATIC COLORECTAL CANCER IN HUMAN AND PRECLINICAL ANIMAL MODEL 345
Method of up-regulating tumor antigen expression using thymalfasin 344
early detection of molecular markers suitable for colorectal cancer diagnosis and therapy in a carcinogenesis model 343
Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application 343
null 342
Preclinical studies using oncofidä-s, a new sn38-hyaluronic acid bioconyugate, for cd44-targeted therapy of colon carcinoma 342
Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. 340
Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery 332
Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo 330
up-regulation of melan-a/mart-1 antigen expression during human melanoma cell differentiation 328
Differentiation of human melanoma cells induced by cyanidin-3-O-beta-glucopyranoside 326
preventive peptide vaccine for colorectal cancer metastases 325
Survivin-Igm Immuno Complex: A Novel Candidate Biomarker Of Cirrhosis To Monitor Patients Progression Towards Hepatocellular Carcinoma 323
Cytoplasmic localization of anthracycline antitumor drugs conjugated with reduced glutathione: a possible correlation with multidrug resistance mechanisms 321
COMBINATION THERAPY WITH THYMOSIN ALPHA-1 POTENTIATES THE ANTITUMOR-ACTIVITY OF INTERLEUKIN-2 WITH CYCLOPHOSPHAMIDE IN THE TREATMENT OF THE LEWIS LUNG-CARCINOMA IN MICE 320
nerve growth factor (ngf): a possible marker for hepatocellular carcinoma (hcc)? 318
Characterization of four newly established melanoma cell lines 312
Influenza della concentrazione di adriamicina su modificazioni volumetriche e proliferazione di cellule leucemiche in vitro 308
Rationale for therapeutic approaches with thymic hormones, interleukin 2 and interferon in combination with chemotherapy. 292
Stimolazione in vivo mediante prostaglandine ed interferone dell'attività natural killer in topi trattati con ciclofosfamide. vol. 87, p. 595-603 290
WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer 284
Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions 206
A new tumour associated antigen of non-small cell lung cancer: Tumour Liberated Proteins (TLP) - A possible new tumor marker 197
Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: A phase-II controlled trial 175
A new tumour associated antigen of non-small cell lung cancer: Tumour liberated proteins (TLP) - A possible new tumor marker 175
Open clinical trial data for all? A view from regulators 161
Sequential biochemotherapy for metastatic colorectal cancer using, fluorouracil, folinic acid, thymopentin and interleukin-2: Clinical and immunological effects 160
BIOCHEMOTHERAPY WITH THYMOSIN-ALPHA-1, INTERLEUKIN-2 AND DACARBAZINE IN PATIENTS WITH METASTATIC MELANOMA - CLINICAL AND IMMUNOLOGICAL EFFECTS 141
Clinical trial publications: A sufficient basis for healthcare decisions? 121
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 119
Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation 102
From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients 102
Asthma, allergy and the olympics: A 12-year survey in elite athletes 96
Innovative medicines: New regulatory procedures for the third millennium 94
Transparency and the European medicines agency - Sharing of clinical trial data 91
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice 88
Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals? 88
Big Data – How to Realize the Promise 87
Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward 87
First-in-human clinical trials - What we can learn from tragic failures 84
European regulatory experience with drugs for central nervous system disorders 84
The impact of parallel regulatory–health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations 81
preventive peptide vaccine for colorectal cancer metastases 77
Drug regulation and pricing - Can regulators influence affordability? 77
Steps forward in regulatory pathways for acute and chronic heart failure 74
Inhibitor of fatty acid amide hydrolase: learning from tragic failures [The editorialists reply] 66
Totale 30.982
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.406
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.406
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.483 0 0 567 687 589 788 663 643 609 577 681 679
2020/20215.532 639 721 643 643 493 693 673 477 156 145 201 48
2021/20221.057 33 123 55 30 27 97 85 41 99 72 62 333
2022/20231.250 137 54 45 135 100 314 103 85 89 12 149 27
2023/2024351 46 9 31 18 35 71 11 11 4 18 15 82
2024/2025988 84 639 265 0 0 0 0 0 0 0 0 0
Totale 31.548